Inhibikase Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Inhibikase Therapeutics's earnings have been declining at an average annual rate of -33.7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 33.7% per year.
Belangrijke informatie
-33.7%
Groei van de winst
-2.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -33.7% |
| Rendement op eigen vermogen | -360.7% |
| Nettomarge | -23,102.2% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25
Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
Aug 26Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Aug 12Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Opbrengsten en kosten
Hoe Inhibikase Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -18 | 7 | 0 |
| 31 Mar 24 | 0 | -19 | 7 | 0 |
| 31 Dec 23 | 0 | -19 | 7 | 0 |
| 30 Sep 23 | 0 | -19 | 7 | 0 |
| 30 Jun 23 | 0 | -19 | 7 | 0 |
| 31 Mar 23 | 0 | -18 | 6 | 0 |
| 31 Dec 22 | 0 | -18 | 6 | 0 |
| 30 Sep 22 | 0 | -19 | 7 | 0 |
| 30 Jun 22 | 0 | -19 | 7 | 0 |
| 31 Mar 22 | 2 | -17 | 7 | 0 |
| 31 Dec 21 | 3 | -15 | 7 | 0 |
| 30 Sep 21 | 3 | -11 | 6 | 0 |
| 30 Jun 21 | 3 | -7 | 5 | 0 |
| 31 Mar 21 | 2 | -5 | 4 | 0 |
| 31 Dec 20 | 1 | -3 | 3 | 0 |
| 30 Sep 20 | 1 | -2 | 2 | 0 |
| 30 Jun 20 | 1 | -3 | 2 | 0 |
| 31 Mar 20 | 1 | -5 | 4 | 0 |
| 31 Dec 19 | 1 | -6 | 4 | 0 |
| 30 Sep 19 | 2 | -7 | 5 | 0 |
| 31 Mar 19 | 4 | -4 | 3 | 0 |
| 31 Dec 18 | 4 | -2 | 3 | 0 |
| 30 Sep 18 | 3 | -1 | 2 | 0 |
| 31 Mar 18 | 3 | 0 | 1 | 0 |
| 31 Dec 17 | 2 | 0 | 1 | 0 |
| 31 Dec 16 | 1 | -1 | 1 | 0 |
Kwaliteitswinsten: IKT is currently unprofitable.
Groeiende winstmarge: IKT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: IKT is unprofitable, and losses have increased over the past 5 years at a rate of 33.7% per year.
Versnelling van de groei: Unable to compare IKT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: IKT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: IKT has a negative Return on Equity (-360.68%), as it is currently unprofitable.